

Vabysmo™ (faricimab-svoa intravitreal)

When requesting Vabysmo™ (faricimab-svoa intravitreal injection) the individual requiring treatment must be diagnosed with one of the following FDA-approved indications and meet the specific coverage guidelines for the covered indication.

FDA-Approved Indications

Vabysmo is indicated for the treatment of patients with:

- Neovascular (wet) age-related macular degeneration (nAMD)
- Diabetic macular edema (DME)
- Macular edema following retinal vein occlusion (RVO)

Coverage Guidelines

Diabetic macular edema (DME), Neovascular (wet) age-related macular degeneration (nAMD), and Macular edema following retinal vein occlusion (RVO)

The individual must meet the following criteria:

- Vabysmo is administered by or under the supervision of an ophthalmologist

Approval duration: 12 months

Dosing Recommendations

Neovascular (Wet) Age-Related Macular Degeneration (AMD)

The recommended dose is 6 mg administered by intravitreal injection not more frequently than every 4 weeks for four doses, followed by not more frequently than once every 8 weeks.

Diabetic Macular Edema (DME)

The recommended dose is 6 mg administered by intravitreal injection not more frequently than once every 4 weeks.

Macular edema following retinal vein occlusion (RVO)

The recommended dose is 6 mg administered by intravitreal injection not more frequently than once every 4 weeks.

References

1. Vabysmo™ intravitreal injection [prescribing information]. South San Francisco, CA: Genentech/Roche; October 2023.